Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Sai Life Sciences IPO
Price Band
₹522.0–549.0
Issue Size
₹3042.62 Cr
Lot Size
27 shares
Min Investment
₹14,823
GMP
+₹72.0 (13.11%)
Issue Price
₹549.0
Subject to Sauda
₹1500
Paid only if allotted
Sai Life Sciences IPO AI Summary
- Sai Life Sciences IPO is listed on BSE, NSE in the Pharmaceuticals sector.
- Price band: ₹522.0–₹549.0 per share, lot size 27 shares (min. investment ₹14,823).
- Subscription window: 11 Dec–13 Dec 2024, listing on 18 Dec 2024.
- Current GMP is +₹72.0 (13.11%), an estimated listing price of ₹621 — unofficial and can change daily.
Sai Life Sciences Limited is an established player in the pharmaceutical sector, offering a wide range of services to global clients. With a strong workforce and a comprehensive service platform, the company aims to leverage its capabilities for growth in the coming years.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Sai Life Sciences IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 13 Dec 2024 — not a current signal.
5 of 6 reviewers say Positive
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Sai Life Sciences IPO Grey Market Premium (GMP) Today
GMP
+₹72.0
GMP %
+13.11%
Est. Listing
₹621.0
Updated: 25 Jul 2026 14:02
About the Company
Incorporated in January 1999, Sai Life Sciences Limited researches, develops, and manufactures small-molecule new chemical entities. The company offers tailor-made services to biotech firms and global pharma companies. In the Financial Year 2024 and for the month ending September 30, 2024, the company provided services to over 280 innovator pharmaceutical companies, including more than 230 in that month alone. Among these clients, the company worked with 18 of the top 25 pharmaceutical companies based on their revenue in the calendar year 2023.The services were offered across countries such as the US, the UK, Europe, and Japan. The company's business development team consists of 16 experienced and qualified professionals, with six located in the US, nine in the UK and Europe, and one in Japan. The company has the following service offerings. Capabilities in chemistry, manufacturing, and control(“CMC”)/contract development and manufacturing organisations (“CDMO”). CRO services include integrated discovery (“Discovery”) capabilities across biology, chemistry, drug metabolism and pharmacokinetics As of September 30, 2024, the company had 2,353 scientific staff, with the majority of the scientific team holding advanced degrees, including 302 Ph. D.s and 1,475 master’s degrees. As of September 30, 2024, the company had 3135 employees with capabilities across the CRDMO value chain. Competitive Strength: As an integrated CRDMO, the company provide a complete platform for discovery, development, and manufacturing. CRO services include integrated discovery capabilities across biology, chemistry, and drug metabolism and pharmacokinetics. CDMO platform with a diverse mix of commercial and under-development molecules
Company Financials (₹ Cr)
As of 2024-09-30
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 2,476.78 | 2,275.14 | 2,186.65 | 2,164.23 |
| Total Income | 693.35 | 1,494.27 | 1,245.11 | 897.74 |
| Profit After Tax | 28.01 | 82.81 | 9.99 | 6.23 |
| NET Worth | 1,044.75 | 974.34 | 887.29 | 877.76 |
| Reserves and Surplus | 1,025.44 | 953.99 | 867.43 | 859.17 |
| Total Borrowing | 764.49 | 710.16 | 699.23 | 751.32 |
Key Ratios
EPS
₹4.34
NAV
₹53.94
ROE
11.79%
ROCE
15.96%
RoNW
8.13%
P/B Value
10.18
P/E Ratio
126.42
Market Cap
₹11418.63 Cr
PAT Margin
5.65%
Peer Comparison
| Company | NAV | RoNW | P/E (x) | EPS Basic | EPS Diluted |
|---|---|---|---|---|---|
| Syngene International Ltd | 105.91 | 11.98% | 73.59 | 12.71 | 12.69 |
| Suven Pharmaceuticals Limited | 94.04 | 14.64% | 109.37 | 11.8 | 11.8 |
| DIVI'S LABORATORIES Limited | 511.21 | 11.79% | 103.04 | 60.27 | 60.27 |
| Sai Life Sciences Limited This IPO | 53.83 | 8.5% | — | 4.57 | 4.53 |
Promoters
Kanumuri Ranga Raju, Krishnam Raju Kanumuri, Kanumuri Mytrey, Sai Quest Syn Pvt.Ltd., Sunflower Partners, Lily Partners, Marigold Partners and Tulip Partners
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by our Company 720.00 2 General corporate purposes 198.98
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total income was ₹897.74 Cr in the year ending 31 Mar 2022, rising to ₹1,245.11 Cr by 31 Mar 2023, and further increasing to ₹1,494.27 Cr by 31 Mar 2024. However, for the period ending 30 Sep 2024, total income was ₹693.35 Cr, which is not directly comparable as it represents a 9-month figure.
Profit Trend
Profit after tax was ₹6.23 Cr in the year ending 31 Mar 2022, increasing to ₹9.99 Cr by 31 Mar 2023, and further rising to ₹82.81 Cr by 31 Mar 2024. For the period ending 30 Sep 2024, profit after tax was ₹28.01 Cr, though this is a 9-month figure, not a full year, so isn't directly comparable.
Valuation
Sai Life Sciences has an implied P/E ratio of 126.42 at the issue price, compared to peers trading at P/E ratios ranging from 73.59 to 109.37.
Grey Market Premium, Explained
The grey market premium (GMP) refers to the price at which shares of an IPO are traded in the unofficial market before they are listed on the stock exchange. A positive GMP indicates strong demand for the shares, while a negative GMP suggests lower interest.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their risk tolerance and investment goals. It's essential to consider the company's growth potential and market conditions.
Who May Want to Wait
Investors who prefer stable returns and are risk-averse may want to avoid IPOs like this, which can be subject to significant price fluctuations in the initial trading period.
IPO Timeline, Explained
The IPO opens for subscription on December 11, 2024, and closes on December 13, 2024. Allotment of shares will be done by December 16, 2024, with the listing expected on December 18, 2024.
Listing Gains — The Risk
Listing-day gains can be unpredictable and depend on market conditions, investor sentiment, and overall demand for the shares. It's important to remember that past performance is not indicative of future results.
This evaluation is generated from Sai Life Sciences's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Sai Life Sciences IPO GMP today?
Sai Life Sciences IPO GMP today is +₹72.0 (13.11%), indicating an estimated listing price of ₹621. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Sai Life Sciences IPO?
The price band of Sai Life Sciences IPO is ₹522.0–₹549.0 per share.
When does Sai Life Sciences IPO open and close?
Sai Life Sciences IPO opens on 11 December 2024 and closes on 13 December 2024.
When does Sai Life Sciences IPO list on the stock exchange?
Sai Life Sciences IPO listed on 18 December 2024 at ₹621.0.
What is the lot size for Sai Life Sciences IPO?
The lot size for Sai Life Sciences IPO is 27 shares, requiring a minimum investment of ₹14,823.
What is the lot size for the IPO?
The lot size for the IPO is 27 shares.
What is the minimum investment required?
The minimum investment required is ₹14,823.
What is the price band for the IPO?
The price band for the IPO is ₹522 to ₹549.
When is the listing date?
The listing date is December 18, 2024.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected premium for shares in the grey market before they are officially listed.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
11 Dec 2024
Close
13 Dec 2024
Allotment
16 Dec 2024
Listing
18 Dec 2024
Similar IPOs in Pharmaceuticals
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Sai Life Sciences?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.